| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Menorrhagia | 29 | 2022 | 82 | 7.710 |
Why?
|
| Vagina | 17 | 2023 | 206 | 4.250 |
Why?
|
| Mullerian Ducts | 12 | 2023 | 46 | 4.160 |
Why?
|
| Urogenital Abnormalities | 10 | 2023 | 167 | 4.030 |
Why?
|
| Vaginal Diseases | 5 | 2023 | 17 | 3.040 |
Why?
|
| Congenital Abnormalities | 10 | 2025 | 300 | 2.780 |
Why?
|
| Gynecology | 8 | 2022 | 129 | 2.370 |
Why?
|
| Ovarian Neoplasms | 11 | 2023 | 463 | 2.280 |
Why?
|
| Adolescent | 86 | 2025 | 20532 | 2.240 |
Why?
|
| Gynecologic Surgical Procedures | 6 | 2021 | 64 | 2.150 |
Why?
|
| Genitalia, Female | 5 | 2020 | 46 | 1.980 |
Why?
|
| Parovarian Cyst | 4 | 2020 | 11 | 1.930 |
Why?
|
| Torsion Abnormality | 6 | 2018 | 36 | 1.920 |
Why?
|
| Uterus | 14 | 2023 | 547 | 1.900 |
Why?
|
| 46, XX Disorders of Sex Development | 5 | 2023 | 26 | 1.770 |
Why?
|
| Female | 113 | 2025 | 70680 | 1.640 |
Why?
|
| von Willebrand Diseases | 9 | 2022 | 54 | 1.570 |
Why?
|
| Laparoscopy | 9 | 2021 | 522 | 1.530 |
Why?
|
| Kidney Diseases | 3 | 2023 | 488 | 1.530 |
Why?
|
| Thrombophilia | 5 | 2016 | 41 | 1.440 |
Why?
|
| Blood Coagulation Disorders | 5 | 2017 | 110 | 1.430 |
Why?
|
| Hymen | 3 | 2025 | 14 | 1.430 |
Why?
|
| Genital Diseases, Female | 4 | 2016 | 30 | 1.420 |
Why?
|
| Kidney | 8 | 2023 | 1333 | 1.390 |
Why?
|
| Ehlers-Danlos Syndrome | 2 | 2021 | 52 | 1.290 |
Why?
|
| Turner Syndrome | 2 | 2023 | 45 | 1.270 |
Why?
|
| Polycystic Ovary Syndrome | 4 | 2021 | 75 | 1.230 |
Why?
|
| Child | 58 | 2025 | 25758 | 1.220 |
Why?
|
| Humans | 122 | 2025 | 132105 | 1.210 |
Why?
|
| Retrospective Studies | 40 | 2025 | 17374 | 1.200 |
Why?
|
| Menstruation Disturbances | 3 | 2025 | 16 | 1.170 |
Why?
|
| Abnormalities, Multiple | 3 | 2023 | 982 | 1.170 |
Why?
|
| Puberty, Precocious | 4 | 2021 | 29 | 1.170 |
Why?
|
| Ureter | 3 | 2021 | 99 | 1.150 |
Why?
|
| Ovarian Diseases | 4 | 2017 | 27 | 1.130 |
Why?
|
| Fibrous Dysplasia, Polyostotic | 2 | 2021 | 7 | 1.080 |
Why?
|
| Aromatase Inhibitors | 3 | 2020 | 78 | 1.070 |
Why?
|
| Adnexal Diseases | 5 | 2019 | 23 | 1.030 |
Why?
|
| Fertility Preservation | 4 | 2020 | 58 | 1.020 |
Why?
|
| Laparotomy | 4 | 2018 | 143 | 1.010 |
Why?
|
| Dysmenorrhea | 4 | 2019 | 15 | 0.970 |
Why?
|
| Obstetrics | 2 | 2022 | 240 | 0.910 |
Why?
|
| Hyperandrogenism | 2 | 2017 | 25 | 0.890 |
Why?
|
| Puberty | 3 | 2016 | 104 | 0.880 |
Why?
|
| Medical Staff | 1 | 2023 | 7 | 0.830 |
Why?
|
| Patient Education as Topic | 2 | 2017 | 461 | 0.820 |
Why?
|
| Disorders of Sex Development | 5 | 2019 | 71 | 0.780 |
Why?
|
| Internship and Residency | 5 | 2022 | 1252 | 0.760 |
Why?
|
| Vaginal Smears | 2 | 2020 | 53 | 0.750 |
Why?
|
| Adnexa Uteri | 3 | 2019 | 9 | 0.730 |
Why?
|
| Young Adult | 21 | 2022 | 9940 | 0.710 |
Why?
|
| Dilatation | 3 | 2017 | 71 | 0.700 |
Why?
|
| Magnetic Resonance Imaging | 13 | 2023 | 3854 | 0.700 |
Why?
|
| Intrauterine Device Expulsion | 1 | 2020 | 3 | 0.690 |
Why?
|
| Pelvic Pain | 3 | 2016 | 28 | 0.690 |
Why?
|
| Hormones | 4 | 2019 | 170 | 0.680 |
Why?
|
| Vulvar Diseases | 2 | 2014 | 11 | 0.670 |
Why?
|
| Papanicolaou Test | 1 | 2020 | 37 | 0.670 |
Why?
|
| Texas | 12 | 2020 | 3630 | 0.670 |
Why?
|
| Cystadenoma, Mucinous | 1 | 2020 | 5 | 0.660 |
Why?
|
| Bone Density | 1 | 2023 | 369 | 0.660 |
Why?
|
| Conservative Treatment | 1 | 2020 | 42 | 0.660 |
Why?
|
| Patient Care Management | 1 | 2020 | 66 | 0.650 |
Why?
|
| Teratoma | 2 | 2021 | 130 | 0.650 |
Why?
|
| Ovary | 5 | 2019 | 371 | 0.630 |
Why?
|
| Endometriosis | 3 | 2014 | 174 | 0.620 |
Why?
|
| Societies, Medical | 1 | 2023 | 778 | 0.600 |
Why?
|
| Contraception | 3 | 2015 | 61 | 0.580 |
Why?
|
| Cysts | 2 | 2012 | 97 | 0.580 |
Why?
|
| Incidence | 8 | 2020 | 3365 | 0.580 |
Why?
|
| Platelet Function Tests | 5 | 2013 | 41 | 0.560 |
Why?
|
| Metrorrhagia | 2 | 2016 | 8 | 0.560 |
Why?
|
| Printing, Three-Dimensional | 1 | 2018 | 69 | 0.550 |
Why?
|
| Hospitals, Pediatric | 7 | 2020 | 780 | 0.550 |
Why?
|
| Wnt Proteins | 2 | 2021 | 223 | 0.530 |
Why?
|
| Robotic Surgical Procedures | 1 | 2021 | 219 | 0.530 |
Why?
|
| Rectovaginal Fistula | 2 | 2016 | 6 | 0.530 |
Why?
|
| Contraceptives, Oral | 2 | 2014 | 41 | 0.520 |
Why?
|
| Genitalia | 2 | 2016 | 38 | 0.520 |
Why?
|
| Peritonitis | 1 | 2017 | 76 | 0.520 |
Why?
|
| Dermoid Cyst | 1 | 2017 | 34 | 0.510 |
Why?
|
| Ultrasonography | 4 | 2019 | 989 | 0.510 |
Why?
|
| Sexual Behavior | 3 | 2013 | 250 | 0.510 |
Why?
|
| Pediatrics | 7 | 2017 | 1208 | 0.500 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2013 | 896 | 0.500 |
Why?
|
| Telemedicine | 1 | 2022 | 506 | 0.500 |
Why?
|
| Menstruation | 2 | 2014 | 28 | 0.490 |
Why?
|
| Neoplasm Recurrence, Local | 5 | 2021 | 1305 | 0.490 |
Why?
|
| Focal Dermal Hypoplasia | 1 | 2016 | 17 | 0.490 |
Why?
|
| Disease Management | 2 | 2017 | 564 | 0.490 |
Why?
|
| Minimally Invasive Surgical Procedures | 3 | 2014 | 194 | 0.490 |
Why?
|
| Fistula | 1 | 2016 | 54 | 0.480 |
Why?
|
| Referral and Consultation | 1 | 2019 | 569 | 0.480 |
Why?
|
| Physicians | 1 | 2022 | 637 | 0.480 |
Why?
|
| Venous Thromboembolism | 2 | 2016 | 186 | 0.480 |
Why?
|
| Interdisciplinary Communication | 1 | 2016 | 133 | 0.480 |
Why?
|
| Hemorrhagic Disorders | 3 | 2022 | 22 | 0.470 |
Why?
|
| Developmental Disabilities | 1 | 2020 | 749 | 0.470 |
Why?
|
| Tumor Burden | 2 | 2016 | 249 | 0.470 |
Why?
|
| Fallopian Tubes | 2 | 2007 | 77 | 0.470 |
Why?
|
| Graft vs Host Disease | 1 | 2020 | 621 | 0.460 |
Why?
|
| Child, Preschool | 16 | 2025 | 14718 | 0.460 |
Why?
|
| Hematocolpos | 1 | 2014 | 1 | 0.460 |
Why?
|
| Diagnosis, Differential | 8 | 2019 | 1966 | 0.460 |
Why?
|
| Hydrocolpos | 1 | 2014 | 2 | 0.450 |
Why?
|
| Mobile Applications | 1 | 2016 | 108 | 0.450 |
Why?
|
| Leuprolide | 1 | 2014 | 23 | 0.450 |
Why?
|
| Hemostatic Disorders | 1 | 2014 | 3 | 0.450 |
Why?
|
| Adenomyosis | 1 | 2014 | 14 | 0.450 |
Why?
|
| Self Care | 1 | 2016 | 227 | 0.450 |
Why?
|
| Blood Platelets | 3 | 2013 | 325 | 0.450 |
Why?
|
| Wound Healing | 1 | 2018 | 480 | 0.440 |
Why?
|
| Hydronephrosis | 1 | 2014 | 38 | 0.440 |
Why?
|
| Blood Platelet Disorders | 2 | 2012 | 14 | 0.440 |
Why?
|
| Lichen Sclerosus et Atrophicus | 1 | 2014 | 4 | 0.440 |
Why?
|
| Eczema | 1 | 2014 | 31 | 0.430 |
Why?
|
| Granulosa Cell Tumor | 2 | 2016 | 39 | 0.430 |
Why?
|
| Fertility | 1 | 2016 | 260 | 0.430 |
Why?
|
| Obesity | 3 | 2017 | 2396 | 0.430 |
Why?
|
| Lighting | 1 | 2014 | 19 | 0.430 |
Why?
|
| Contraceptives, Oral, Synthetic | 1 | 2013 | 5 | 0.430 |
Why?
|
| Norethindrone | 1 | 2013 | 8 | 0.430 |
Why?
|
| Vulva | 2 | 2022 | 16 | 0.420 |
Why?
|
| Lacerations | 1 | 2014 | 33 | 0.420 |
Why?
|
| Medical History Taking | 3 | 2010 | 114 | 0.410 |
Why?
|
| Pubic Bone | 1 | 2013 | 2 | 0.400 |
Why?
|
| Pilot Projects | 5 | 2020 | 1451 | 0.400 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2014 | 265 | 0.400 |
Why?
|
| Crohn Disease | 1 | 2016 | 290 | 0.390 |
Why?
|
| Fallopian Tube Diseases | 1 | 2012 | 8 | 0.380 |
Why?
|
| Hematologic Diseases | 2 | 2012 | 82 | 0.380 |
Why?
|
| Surgically-Created Structures | 2 | 2014 | 5 | 0.380 |
Why?
|
| Safe Sex | 1 | 2012 | 16 | 0.380 |
Why?
|
| Problem-Based Learning | 2 | 2009 | 72 | 0.380 |
Why?
|
| Ovariectomy | 4 | 2018 | 171 | 0.380 |
Why?
|
| Prospective Studies | 8 | 2023 | 6530 | 0.370 |
Why?
|
| Groin | 1 | 2011 | 14 | 0.370 |
Why?
|
| Cervix Uteri | 2 | 2009 | 64 | 0.370 |
Why?
|
| Hair Removal | 1 | 2011 | 8 | 0.370 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2020 | 1192 | 0.370 |
Why?
|
| Catheters | 1 | 2012 | 89 | 0.370 |
Why?
|
| Abscess | 1 | 2013 | 140 | 0.360 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2012 | 95 | 0.350 |
Why?
|
| Risk Reduction Behavior | 1 | 2012 | 147 | 0.350 |
Why?
|
| Menarche | 4 | 2017 | 36 | 0.350 |
Why?
|
| Postoperative Complications | 4 | 2018 | 3146 | 0.350 |
Why?
|
| Thrombosis | 3 | 2015 | 530 | 0.350 |
Why?
|
| Constriction, Pathologic | 3 | 2021 | 235 | 0.350 |
Why?
|
| Infertility, Female | 2 | 2014 | 149 | 0.340 |
Why?
|
| Nitriles | 1 | 2011 | 155 | 0.340 |
Why?
|
| Adolescent Behavior | 1 | 2013 | 171 | 0.340 |
Why?
|
| Triazoles | 1 | 2011 | 147 | 0.340 |
Why?
|
| Contraceptives, Oral, Combined | 3 | 2017 | 16 | 0.340 |
Why?
|
| Hypertension, Pulmonary | 2 | 2012 | 464 | 0.330 |
Why?
|
| Cohort Studies | 7 | 2020 | 5150 | 0.330 |
Why?
|
| Adult | 18 | 2022 | 31557 | 0.330 |
Why?
|
| Health Education | 1 | 2012 | 235 | 0.330 |
Why?
|
| Osteomyelitis | 1 | 2013 | 214 | 0.320 |
Why?
|
| Recurrence | 3 | 2020 | 1454 | 0.320 |
Why?
|
| Sex Cord-Gonadal Stromal Tumors | 1 | 2009 | 12 | 0.320 |
Why?
|
| Anemia | 4 | 2022 | 349 | 0.320 |
Why?
|
| Pregnancy | 8 | 2022 | 7551 | 0.320 |
Why?
|
| Colposcopy | 1 | 2009 | 16 | 0.310 |
Why?
|
| Ovarian Cysts | 3 | 2019 | 23 | 0.310 |
Why?
|
| Misoprostol | 1 | 2009 | 27 | 0.310 |
Why?
|
| Oxytocics | 1 | 2009 | 28 | 0.310 |
Why?
|
| DNA Copy Number Variations | 1 | 2014 | 1035 | 0.300 |
Why?
|
| Surveys and Questionnaires | 6 | 2022 | 3982 | 0.300 |
Why?
|
| Estrogens | 4 | 2017 | 435 | 0.290 |
Why?
|
| Phenotype | 4 | 2017 | 4541 | 0.290 |
Why?
|
| Infant | 11 | 2025 | 13039 | 0.290 |
Why?
|
| Levonorgestrel | 2 | 2019 | 20 | 0.290 |
Why?
|
| Prevalence | 3 | 2021 | 2659 | 0.280 |
Why?
|
| Family Practice | 1 | 2008 | 89 | 0.280 |
Why?
|
| Canada | 2 | 2022 | 341 | 0.270 |
Why?
|
| Genome-Wide Association Study | 1 | 2014 | 1830 | 0.260 |
Why?
|
| Asthma | 1 | 2014 | 771 | 0.260 |
Why?
|
| Thromboembolism | 1 | 2007 | 93 | 0.260 |
Why?
|
| Adrenal Hyperplasia, Congenital | 2 | 2018 | 34 | 0.250 |
Why?
|
| Gonadal Steroid Hormones | 3 | 2011 | 91 | 0.250 |
Why?
|
| Tertiary Care Centers | 2 | 2020 | 260 | 0.250 |
Why?
|
| Practice Guidelines as Topic | 4 | 2020 | 1306 | 0.240 |
Why?
|
| Dyspareunia | 2 | 2016 | 8 | 0.240 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2014 | 2851 | 0.240 |
Why?
|
| Rickettsia Infections | 1 | 2005 | 7 | 0.230 |
Why?
|
| Clinical Competence | 2 | 2009 | 1071 | 0.230 |
Why?
|
| Ligaments | 1 | 2005 | 21 | 0.230 |
Why?
|
| Disseminated Intravascular Coagulation | 1 | 2005 | 67 | 0.230 |
Why?
|
| Cross-Sectional Studies | 4 | 2022 | 3738 | 0.230 |
Why?
|
| Hirsutism | 2 | 2017 | 24 | 0.230 |
Why?
|
| Ultrasonic Therapy | 1 | 2004 | 28 | 0.230 |
Why?
|
| Body Mass Index | 3 | 2020 | 1700 | 0.220 |
Why?
|
| Hematoma | 1 | 2005 | 92 | 0.220 |
Why?
|
| Infant, Newborn | 4 | 2023 | 8538 | 0.210 |
Why?
|
| Treatment Outcome | 10 | 2016 | 13017 | 0.210 |
Why?
|
| Internet | 3 | 2013 | 405 | 0.210 |
Why?
|
| Comorbidity | 3 | 2016 | 1606 | 0.210 |
Why?
|
| Equipment Design | 2 | 2017 | 611 | 0.200 |
Why?
|
| Gonadotropin-Releasing Hormone | 2 | 2014 | 77 | 0.200 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2023 | 50 | 0.200 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 2023 | 97 | 0.200 |
Why?
|
| Education, Medical, Graduate | 1 | 2008 | 564 | 0.200 |
Why?
|
| Contraceptive Agents, Female | 2 | 2016 | 31 | 0.200 |
Why?
|
| Abdominal Pain | 3 | 2014 | 314 | 0.190 |
Why?
|
| Absorptiometry, Photon | 1 | 2023 | 204 | 0.190 |
Why?
|
| Patient Compliance | 2 | 2016 | 473 | 0.190 |
Why?
|
| Fibrinolytic Agents | 2 | 2017 | 207 | 0.190 |
Why?
|
| Hemorrhage | 3 | 2022 | 518 | 0.190 |
Why?
|
| Health Surveys | 2 | 2013 | 259 | 0.180 |
Why?
|
| Antifibrinolytic Agents | 3 | 2017 | 49 | 0.180 |
Why?
|
| Risk Factors | 5 | 2020 | 10902 | 0.180 |
Why?
|
| Amenorrhea | 2 | 2014 | 20 | 0.180 |
Why?
|
| United States | 5 | 2022 | 11627 | 0.180 |
Why?
|
| Contraceptive Agents | 2 | 2013 | 14 | 0.180 |
Why?
|
| Hospitals, Teaching | 2 | 2011 | 113 | 0.180 |
Why?
|
| Wolffian Ducts | 1 | 2021 | 10 | 0.180 |
Why?
|
| von Willebrand Factor | 3 | 2022 | 194 | 0.170 |
Why?
|
| Gynecological Examination | 1 | 2020 | 3 | 0.170 |
Why?
|
| Diagnostic Errors | 1 | 2025 | 348 | 0.170 |
Why?
|
| Hirschsprung Disease | 1 | 2020 | 38 | 0.160 |
Why?
|
| Disease Susceptibility | 2 | 2011 | 292 | 0.160 |
Why?
|
| International Classification of Diseases | 1 | 2020 | 98 | 0.160 |
Why?
|
| Reproductive Health | 1 | 2020 | 49 | 0.160 |
Why?
|
| Neurodegenerative Diseases | 1 | 2022 | 281 | 0.150 |
Why?
|
| Constipation | 1 | 2020 | 128 | 0.150 |
Why?
|
| Postpartum Hemorrhage | 1 | 2020 | 110 | 0.150 |
Why?
|
| Salpingectomy | 1 | 2018 | 15 | 0.150 |
Why?
|
| Patient Care Team | 2 | 2016 | 572 | 0.150 |
Why?
|
| Multiple Sclerosis | 1 | 2022 | 382 | 0.150 |
Why?
|
| Sus scrofa | 1 | 2018 | 123 | 0.140 |
Why?
|
| Mechanotransduction, Cellular | 1 | 2018 | 74 | 0.140 |
Why?
|
| Follow-Up Studies | 4 | 2019 | 5399 | 0.140 |
Why?
|
| Syndrome | 3 | 2021 | 1173 | 0.140 |
Why?
|
| Biomechanical Phenomena | 1 | 2018 | 261 | 0.140 |
Why?
|
| Bone Marrow Transplantation | 1 | 2020 | 617 | 0.130 |
Why?
|
| Blood Coagulation | 2 | 2009 | 129 | 0.130 |
Why?
|
| Cicatrix | 1 | 2018 | 124 | 0.130 |
Why?
|
| Engineering | 1 | 2017 | 7 | 0.130 |
Why?
|
| Salvage Therapy | 1 | 2018 | 201 | 0.130 |
Why?
|
| MP3-Player | 1 | 2016 | 7 | 0.130 |
Why?
|
| Dexamethasone | 1 | 2018 | 274 | 0.130 |
Why?
|
| Patient Selection | 1 | 2020 | 732 | 0.130 |
Why?
|
| Intrauterine Devices, Medicated | 1 | 2016 | 6 | 0.130 |
Why?
|
| Ovulation Induction | 1 | 2016 | 42 | 0.120 |
Why?
|
| Elasticity Imaging Techniques | 1 | 2018 | 142 | 0.120 |
Why?
|
| Ligation | 1 | 2016 | 139 | 0.120 |
Why?
|
| Uterine Hemorrhage | 1 | 2016 | 43 | 0.120 |
Why?
|
| Focus Groups | 1 | 2017 | 220 | 0.120 |
Why?
|
| Organ Sparing Treatments | 1 | 2016 | 43 | 0.120 |
Why?
|
| Wnt Signaling Pathway | 1 | 2017 | 204 | 0.120 |
Why?
|
| Specialties, Surgical | 1 | 2017 | 85 | 0.120 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2017 | 305 | 0.120 |
Why?
|
| Androgen-Insensitivity Syndrome | 1 | 2015 | 26 | 0.120 |
Why?
|
| Chronic Disease | 1 | 2020 | 1226 | 0.120 |
Why?
|
| Progesterone | 1 | 2017 | 450 | 0.120 |
Why?
|
| Colpotomy | 1 | 2014 | 7 | 0.110 |
Why?
|
| Pandemics | 1 | 2022 | 1187 | 0.110 |
Why?
|
| Inguinal Canal | 1 | 2014 | 13 | 0.110 |
Why?
|
| Office Management | 1 | 2014 | 4 | 0.110 |
Why?
|
| Cardiovascular Diseases | 1 | 2007 | 2059 | 0.110 |
Why?
|
| Sexual Maturation | 1 | 2014 | 46 | 0.110 |
Why?
|
| Consensus | 2 | 2022 | 656 | 0.110 |
Why?
|
| Tranexamic Acid | 1 | 2014 | 33 | 0.110 |
Why?
|
| Tissue Adhesions | 1 | 2014 | 25 | 0.110 |
Why?
|
| Optical Fibers | 1 | 2014 | 19 | 0.110 |
Why?
|
| Kidney Tubules, Proximal | 1 | 2014 | 74 | 0.110 |
Why?
|
| Hot Flashes | 1 | 2013 | 7 | 0.110 |
Why?
|
| Contraindications | 1 | 2013 | 76 | 0.100 |
Why?
|
| Natural Family Planning Methods | 1 | 2013 | 2 | 0.100 |
Why?
|
| Contraceptive Devices | 1 | 2013 | 2 | 0.100 |
Why?
|
| Nausea | 1 | 2013 | 83 | 0.100 |
Why?
|
| Information Seeking Behavior | 1 | 2013 | 16 | 0.100 |
Why?
|
| Case-Control Studies | 1 | 2020 | 3418 | 0.100 |
Why?
|
| ROC Curve | 1 | 2015 | 598 | 0.100 |
Why?
|
| Treatment Refusal | 1 | 2013 | 80 | 0.100 |
Why?
|
| Qualitative Research | 1 | 2017 | 663 | 0.100 |
Why?
|
| Ovarian Follicle | 1 | 2014 | 124 | 0.100 |
Why?
|
| Tomography, Optical Coherence | 1 | 2018 | 573 | 0.100 |
Why?
|
| Operative Time | 1 | 2014 | 192 | 0.100 |
Why?
|
| Vomiting | 1 | 2013 | 108 | 0.100 |
Why?
|
| Sensitivity and Specificity | 2 | 2015 | 2142 | 0.100 |
Why?
|
| Mood Disorders | 1 | 2013 | 129 | 0.100 |
Why?
|
| Chronic Pain | 1 | 2014 | 148 | 0.100 |
Why?
|
| Risk-Taking | 1 | 2013 | 101 | 0.100 |
Why?
|
| Endocrinology | 1 | 2014 | 128 | 0.100 |
Why?
|
| Adolescent Health Services | 1 | 2012 | 34 | 0.090 |
Why?
|
| Reproductive Health Services | 1 | 2012 | 19 | 0.090 |
Why?
|
| Ambulatory Care Facilities | 1 | 2014 | 241 | 0.090 |
Why?
|
| Body Piercing | 1 | 2011 | 4 | 0.090 |
Why?
|
| Lip | 1 | 2011 | 17 | 0.090 |
Why?
|
| Educational Status | 2 | 2009 | 294 | 0.090 |
Why?
|
| Single-Blind Method | 1 | 2012 | 242 | 0.090 |
Why?
|
| Models, Psychological | 1 | 2012 | 144 | 0.090 |
Why?
|
| Pain | 1 | 2014 | 462 | 0.090 |
Why?
|
| Neoplasm Staging | 3 | 2023 | 1368 | 0.090 |
Why?
|
| Exons | 1 | 2014 | 802 | 0.090 |
Why?
|
| Brain | 2 | 2022 | 3201 | 0.090 |
Why?
|
| Abdomen | 1 | 2011 | 135 | 0.090 |
Why?
|
| Neural Tube Defects | 1 | 2014 | 359 | 0.090 |
Why?
|
| Chi-Square Distribution | 1 | 2012 | 586 | 0.090 |
Why?
|
| T-Box Domain Proteins | 2 | 2022 | 122 | 0.090 |
Why?
|
| Reoperation | 2 | 2016 | 854 | 0.080 |
Why?
|
| Sexuality | 1 | 2010 | 13 | 0.080 |
Why?
|
| Medication Adherence | 1 | 2013 | 326 | 0.080 |
Why?
|
| Linear Models | 1 | 2012 | 710 | 0.080 |
Why?
|
| Administration, Intravaginal | 1 | 2009 | 9 | 0.080 |
Why?
|
| Age Determination by Skeleton | 1 | 2009 | 11 | 0.080 |
Why?
|
| Pregnancy Complications, Hematologic | 1 | 2009 | 29 | 0.080 |
Why?
|
| Adrenarche | 1 | 2009 | 11 | 0.080 |
Why?
|
| Personal Satisfaction | 1 | 2010 | 105 | 0.080 |
Why?
|
| Male | 7 | 2016 | 64918 | 0.080 |
Why?
|
| Pregnancy Complications | 1 | 2014 | 550 | 0.080 |
Why?
|
| Uterine Cervical Dysplasia | 1 | 2009 | 32 | 0.080 |
Why?
|
| Women's Health | 1 | 2010 | 148 | 0.070 |
Why?
|
| Prognosis | 2 | 2016 | 5008 | 0.070 |
Why?
|
| Length of Stay | 1 | 2014 | 1381 | 0.070 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2021 | 399 | 0.070 |
Why?
|
| Program Development | 2 | 2020 | 191 | 0.070 |
Why?
|
| Registries | 1 | 2014 | 1589 | 0.070 |
Why?
|
| Preoperative Care | 1 | 2009 | 370 | 0.060 |
Why?
|
| Mutation | 1 | 2021 | 6249 | 0.060 |
Why?
|
| Biomarkers, Tumor | 1 | 2015 | 1683 | 0.060 |
Why?
|
| Age Factors | 1 | 2013 | 2922 | 0.060 |
Why?
|
| Endometrium | 1 | 2009 | 274 | 0.060 |
Why?
|
| Risk | 1 | 2008 | 761 | 0.060 |
Why?
|
| Deamino Arginine Vasopressin | 2 | 2017 | 9 | 0.060 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2009 | 261 | 0.060 |
Why?
|
| Ice | 1 | 2005 | 5 | 0.060 |
Why?
|
| Immunohistochemistry | 1 | 2009 | 1723 | 0.060 |
Why?
|
| Cryotherapy | 1 | 2005 | 21 | 0.060 |
Why?
|
| Wounds, Nonpenetrating | 1 | 2007 | 222 | 0.060 |
Why?
|
| Blood Coagulation Tests | 1 | 2005 | 62 | 0.060 |
Why?
|
| Sexual Development | 2 | 2019 | 24 | 0.060 |
Why?
|
| Hysteroscopy | 1 | 2004 | 13 | 0.060 |
Why?
|
| Sertoli-Leydig Cell Tumor | 1 | 2004 | 18 | 0.050 |
Why?
|
| Decision Making | 1 | 2009 | 694 | 0.050 |
Why?
|
| Predictive Value of Tests | 1 | 2007 | 2306 | 0.040 |
Why?
|
| Paternal Inheritance | 1 | 2021 | 11 | 0.040 |
Why?
|
| PAX8 Transcription Factor | 1 | 2021 | 16 | 0.040 |
Why?
|
| Genetic Pleiotropy | 1 | 2021 | 28 | 0.040 |
Why?
|
| Bone Morphogenetic Protein 7 | 1 | 2021 | 24 | 0.040 |
Why?
|
| Bone Morphogenetic Protein 4 | 1 | 2021 | 39 | 0.040 |
Why?
|
| Spinal Cord | 1 | 2022 | 276 | 0.040 |
Why?
|
| Penetrance | 1 | 2021 | 113 | 0.040 |
Why?
|
| Cloaca | 1 | 2020 | 15 | 0.040 |
Why?
|
| Codon, Nonsense | 1 | 2021 | 144 | 0.040 |
Why?
|
| Pelvic Floor | 1 | 2020 | 39 | 0.040 |
Why?
|
| Virilism | 1 | 2018 | 14 | 0.040 |
Why?
|
| Middle Aged | 2 | 2017 | 28936 | 0.040 |
Why?
|
| Homeodomain Proteins | 1 | 2021 | 573 | 0.030 |
Why?
|
| Hemostatics | 1 | 2017 | 60 | 0.030 |
Why?
|
| Animals | 1 | 2018 | 34953 | 0.030 |
Why?
|
| Menopause | 1 | 2017 | 90 | 0.030 |
Why?
|
| Genetic Association Studies | 1 | 2021 | 856 | 0.030 |
Why?
|
| Exome | 1 | 2022 | 1086 | 0.030 |
Why?
|
| Hospitalization | 1 | 2005 | 1891 | 0.030 |
Why?
|
| RNA, Messenger | 1 | 2022 | 2679 | 0.030 |
Why?
|
| Delayed Diagnosis | 1 | 2017 | 133 | 0.030 |
Why?
|
| Blood Transfusion | 1 | 2017 | 293 | 0.030 |
Why?
|
| Mentoring | 1 | 2017 | 83 | 0.030 |
Why?
|
| Gonads | 1 | 2015 | 34 | 0.030 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2017 | 237 | 0.030 |
Why?
|
| Contraceptives, Oral, Hormonal | 1 | 2014 | 20 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2017 | 1255 | 0.030 |
Why?
|
| Disclosure | 1 | 2015 | 153 | 0.030 |
Why?
|
| Prenatal Diagnosis | 1 | 2018 | 634 | 0.030 |
Why?
|
| Drug Combinations | 1 | 2014 | 281 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2017 | 1296 | 0.030 |
Why?
|
| Faculty, Medical | 1 | 2017 | 278 | 0.030 |
Why?
|
| Cross-Over Studies | 1 | 2014 | 324 | 0.030 |
Why?
|
| Platelet Aggregation | 1 | 2013 | 107 | 0.030 |
Why?
|
| Androgens | 1 | 2015 | 277 | 0.020 |
Why?
|
| Logistic Models | 1 | 2017 | 1837 | 0.020 |
Why?
|
| Informed Consent | 1 | 2015 | 346 | 0.020 |
Why?
|
| Surgeons | 1 | 2017 | 284 | 0.020 |
Why?
|
| Neurosurgical Procedures | 1 | 2014 | 320 | 0.020 |
Why?
|
| Epistaxis | 1 | 2011 | 12 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2014 | 1672 | 0.020 |
Why?
|
| Transcription Factors | 1 | 2021 | 2494 | 0.020 |
Why?
|
| Evidence-Based Medicine | 1 | 2014 | 670 | 0.020 |
Why?
|
| Polymorphism, Genetic | 1 | 2014 | 803 | 0.020 |
Why?
|
| Lubricants | 1 | 2010 | 3 | 0.020 |
Why?
|
| Arousal | 1 | 2010 | 81 | 0.020 |
Why?
|
| Health Status Indicators | 1 | 2010 | 127 | 0.020 |
Why?
|
| Gender Identity | 1 | 2009 | 74 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2010 | 1008 | 0.020 |
Why?
|
| Acute Disease | 1 | 2011 | 1161 | 0.020 |
Why?
|
| Pelvic Bones | 1 | 2007 | 28 | 0.020 |
Why?
|
| Terminology as Topic | 1 | 2009 | 232 | 0.020 |
Why?
|
| Adaptation, Psychological | 1 | 2010 | 455 | 0.020 |
Why?
|
| Accidents, Traffic | 1 | 2007 | 109 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2010 | 1443 | 0.020 |
Why?
|
| Psychometrics | 1 | 2010 | 693 | 0.020 |
Why?
|
| Stress, Psychological | 1 | 2010 | 578 | 0.010 |
Why?
|
| Time Factors | 1 | 2015 | 6445 | 0.010 |
Why?
|
| Quality of Life | 1 | 2014 | 2152 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2010 | 3021 | 0.010 |
Why?
|
| Endoscopy | 1 | 2004 | 281 | 0.010 |
Why?
|
| Neoplasms | 1 | 2015 | 2953 | 0.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2004 | 1348 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2004 | 2171 | 0.010 |
Why?
|
| Aged | 1 | 2010 | 21413 | 0.010 |
Why?
|